Bass set for first IPR trial as Shire petition proceeds

Hedge fund manger Kyle Bass has secured his first inter partes review (IPR) trial after the Patent Trial and Appeal Board (PTAB) instituted a challenge against a patent owned by biopharmaceutical company Shire.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Kyle Bass tastes second success at the PTAB

27 October 2015 Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board for the second time in a month after it agreed to institute an inter partes review of a patent covering a drug owned by NPS Pharmaceuticals.

Americas

PTAB deals Bass another blow

21 October 2015 The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

Americas

Bass suffers another IPR setback

3 September 2015 Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.

More on this story

Americas

Kyle Bass tastes second success at the PTAB

Americas

PTAB deals Bass another blow

21 October 2015 The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

Americas

Bass suffers another IPR setback

More on this story

Americas

Kyle Bass tastes second success at the PTAB

Americas

PTAB deals Bass another blow

21 October 2015 The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

Americas

Bass suffers another IPR setback